ABOUT
Standard Biotools
Standard BioTools (used the name start from 6 April, 2022), previously known as Fluidigm (founded in 1999), is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health.
As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry, Imaging mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes.
We works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.
